Nonclinical safety evaluation,pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies |
| |
| Authors: | Lone Fjord-Larsen,Annemette Thougaard,Karen Malene Wegener,Joan Christiansen,Frank Larsen,Lise Maj Schrø der-Hansen,Marianne Kaarde,Dorte Kornerup Ditlevsen |
| |
| Affiliation: | aDepartment Regulatory Toxicology and Safety Assessment, H. Lundbeck A/S, Valby, Denmark;bDepartment Exploratory Toxicology, H. Lundbeck A/S, Valby, Denmark;cDepartment PKPD Modelling and Simulation, H. Lundbeck A/S, Valby, Denmark;dDepartment Bioanalysis-Biologics, H. Lundbeck A/S, Valby, Denmark |
| |
| Abstract: | |
| |
| Keywords: | |
|
|
